LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) recently featured in a new episode of The Balancing Act® on Lifetime TV, focusing on autoimmune Pulmonary Alveolar Proteinosis (aPAP). This episode, part of the series Behind the Mystery™, highlights the diagnostic journey of an aPAP patient and aims to raise awareness about this rare condition.
The broadcast includes insights from Dr. Bruce Trapnell, Professor of Medicine and Pediatrics at the University of Cincinnati College of Medicine, who is also the International Coordinating Investigator for Savara’s IMPALA-2 Phase 3 clinical trial. This trial is examining the efficacy of molgramostim inhalation solution as a potential treatment for aPAP. A replay of the episode can be viewed at https://bit.ly/480OPyy.
Matt Pauls, Chair and CEO of Savara, expressed the company’s commitment to addressing the unmet needs of the aPAP community. He emphasized the importance of educating the public on the symptoms and diagnosis of aPAP, particularly through a simple, non-invasive blood test, which could lead to faster diagnosis and treatment.
Savara’s dedication to advancing treatment options for aPAP is underscored by their ongoing efforts to submit a Biologics License Application (BLA) for molgramostim to the U.S. Food and Drug Administration, expected in the first half of 2025. The company’s involvement in the episode reflects its commitment to improving awareness and treatment of rare diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.